Clinical trials: Transplant Failure, open to volunteers
Severe Aplastic Anemia, Hypo-Plastic MDS
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Background: Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant.
- Conditions
- Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT03173937
- Testing
- Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
End-Stage Renal Disease
Views on Information Resources for Kidney Transplantation Patients
The goal of this pilot study is to find out whether educational videos can help patients better understand, and remember, important information regarding the benefits and risks of having a kidney transplant.
- Trial name
- NCT07017556
- Testing
- Views on Information Resources for Kidney Transplantation Patients
- Where
- New Zealand
- Volunteers
- 60 people
- Sponsor
- University of Auckland, New Zealand
Highly Sensitized Patients Awaiting Kidney Transplant
CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants
The purpose of this study is to assess the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with ESKD awaiting kidney transplant-who, as assessed by investigators, are improbable…
- Trial name
- NCT07350837
- Testing
- AZD0120
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tongji Hospital
Liver Transplantation
Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation
Liver transplantation carries a substantial risk of bleeding, making precise haemostasis control essential, although assessing coagulation remains challenging.
- Trial name
- QUALIVERT (NCT06749405)
- Testing
- Transfusion algorithm based on Quantra®, Conventional transfusion algorithm
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Toulouse
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)
- Trial name
- NCT07796620
- Testing
- Sirolimus, Ruxolitinib, MMF
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Heart Failure
Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial
This is a single-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in elderly patients with heart failure with preserved ejection…
- Trial name
- NCT07628777
- Testing
- Fecal Microbiota Transplantation (FMT) Capsules
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University
Hematopoietic Stem Cell Transplantation, Graft Failure
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft…
- Trial name
- NCT07244419
- Testing
- Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Background: Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia.
- Trial name
- NCT01174108
- Testing
- Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
An open-label, single-arm clinical trial to evaluate the safety and efficacy of gecacitinib tablets in patients with acute graft-versus-host disease (GVHD) who have failed or are intolerant to ruxolitinib-containing second-line…
- Trial name
- GRIT (NCT07197112)
- Testing
- Gecacitinib
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Diaphragm Injury, Respiratory Failure
Diaphragm Structure and Pathobiology in Patients Being Bridged to Lung Transplant
This study is designed to characterize the changes in diaphragm structure, function and biology during bridging to lung transplant by mechanical ventilation or extracorporeal life support.
- Conditions
- Diaphragm Injury, Respiratory Failure, Mechanical Ventilation Complication
- Trial name
- DIASPORA (NCT03667027)
- Testing
- Respiratory support
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Chronic Heart Failure
Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure
The purpose of this study is to determine whether people with CHF, who often have different gut bacteria from healthy, would benefit from replacing their gut bacteria with healthy donor bacteria (also known as Intestinal…
- Trial name
- IMT (NCT07490054)
- Testing
- MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Melana Yuzefpolskaya, MD
Heart Failure, Revascularization
Percutaneous Coronary RevascularizatiOn VERsus Coronary-Artery Bypass Grafting for Multivessel Disease in Patients With Left Ventricular Dysfunction (PROVERB)
A short description, 5000 characters Ischemic cardiomyopathy related to coronary artery disease is currently the leading cause of heart failure.
- Trial name
- PROVERB (NCT05532631)
- Testing
- Percutaneous coronary intervention, Coronary artery bypass grafting
- Where
- France
- Volunteers
- 1,040 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Aplastic Anemia, Aplastic Anaemia
A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.
- Conditions
- Severe Aplastic Anemia, Aplastic Anaemia, Hematopoietic Cell Transplant
- Trial name
- NCT07586735
- Testing
- BFCA conditiong regimen
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University People's Hospital
Heart Failure
XVIVO Heart Transplant Study in Clinical Practice
HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting.
- Trial name
- HOPE for All (NCT07556588)
- Testing
- XVIVO Heart Assist Transport System
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- XVIVO Perfusion
End Stage Liver Disease, Hepatocellular Carcinoma
Vienna Hypothermic Oxygenated Machine Perfusion Study
In this observational cohort study data on all patients undergoing liver transplantation after hypothermic oxygenated machine perfusion at Medical University of Vienna will be prospectively recorded.
- Trial name
- VIHOMPS (NCT06418165)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Kidney Transplantation in Highly Sensitized Patients
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
- Trial name
- DINKY (NCT05753930)
- Testing
- Imlifidase
- Where
- 6 sites in Finland, France and 3 more
- Volunteers
- 10 people
- Sponsor
- Hansa Biopharma AB
Congestive Heart Failure
Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease
Hypothesis: Tissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of…
- Trial name
- NCT01099982
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Utah